News und Analysen

Biotech company Novavax (NASDAQ: NVAX) went from being relatively unknown just four years ago to becoming one of the U.S. COVID-19 vaccine market leaders. The company has faced many trials and

Shares of Pfizer (NYSE: PFE) were sinking 4.4% lower as of 11:10 a.m. ET on Friday after falling as much as 7.1% earlier in the morning. The sell-off came after the company announced that it's

Biotech companies CRISPR Therapeutics (NASDAQ: CRSP) and Vertex Pharmaceuticals (NASDAQ: VRTX) are often mentioned in the same sentence. That's because they have been partnering to develop a

The big asset buy in the healthcare industry provided a healthy pop to the two companies involved on Thursday. The stock price of the buyer, sector mainstay AbbVie (NYSE: ABBV), enjoyed a nearly 3%

Since its split from Abbott Laboratories in 2013, AbbVie (NYSE: ABBV) has been the third best-performing stock in terms of total returns on capital (assuming the dividend was reinvested) on the

Pfizer's (NYSE: PFE) stock performance has been disappointing this year (down 38%). The company has faced multiple challenges, such as declining revenues from COVID-19 products, looming patent

Are you a pro when it comes to procrastination? Some investors take so long to make a decision on buying stocks that they miss out on great upside moves. And when those stocks pay juicy dividends

Some investors intend to hold shares of the companies they own for good, never having to sell them. This strategy makes sense. Warren Buffett, the man widely regarded as the greatest contemporary

If you want an investment to make you a millionaire, you need three things. The first is some decent money to invest in the stock market, ideally at least $20,000. The second is time and patience --

Last year, pharmaceutical giant Pfizer (NYSE: PFE) reported the highest revenue it had ever had in a single calendar year. But in 2023, the drugmaker has substantially underperformed the market, and

Novo Nordisk's (NYSE: NVO) Ozempic is indicated to treat diabetes, and its wild success and household name is making a few cardiometabolic device companies rather nervous. With a powerful tool to

Last year, tech giant Amazon (NASDAQ: AMZN) and medical device specialist DexCom (NASDAQ: DXCM) were among the several high-profile companies to conduct stock splits. This move attracted plenty of

All eyes have been on CRISPR Therapeutics (NASDAQ: CRSP) in recent times because the biotech company has reached a key moment. CRISPR Therapeutics and partner Vertex Pharmaceuticals are awaiting

When it comes to gene-editing companies on the cutting edge, Beam Therapeutics (NASDAQ: BEAM) is keen to be one of the leaders. While it's a bit of a laggard in terms of its pipeline's maturity

Most, if not all, of the market's current mega-cap stocks started out much smaller. Investors who spotted their potential early had opportunities to make fortunes over time.

Which smaller stocks

The biotech company that's able to deliver the next game-changing treatment might become tomorrow's winner -- and offer your portfolio a giant boost.

Problem is, it's not always easy to identify

Shares of CRISPR Therapeutics (NASDAQ: CRSP) were jumping 10.1% higher as of 10:58 a.m. ET on Friday. The solid move followed Thursday's gain of more than 8%.

There's a good reason for this

With shares of DexCom (NASDAQ: DXCM) falling 11% this year amid a steadily rising market, one might think that the medical device maker's growth potential is ebbing compared to its former glory. But

Getting to $1 million is a great long-term goal for investors to target. Not only could that be a good nest egg to tap into during retirement, but you could also use that money to invest in dividend

If past performance guaranteed future success, Vertex Pharmaceuticals (NASDAQ: VRTX) would be one of the best biotech stocks to invest in. The drugmaker has consistently outperformed the broader

AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) are makers of two of the world's top-selling pharmaceutical products. AbbVie's immunology drug Humira brought in peak sales of more than $21 billion, while

Wall Street traders have numerous (and often creative) strategies to speculate on stocks and their up and down price movements. There are times when the prices of stocks are influenced more by what

Image source: The Motley Fool.

CorMedix (NASDAQ: CRMD)Q3 2023 Earnings CallNov 14, 2023, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com

Both Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO) can claim to investors that plenty more growth is on the way. With new markets beckoning and multi-year strategic plans in full swing, both of